Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma

A vizsgálat adatai

Ki végzi

University Children's Hospital Basel

Azonosító

NCT07472283

A regiszteradat frissítve

2026. március 16.

Eredeti leírás

This study is to evaluate the efficacy of the digital health assistant (DHA) "Alex" in improving asthma control in asthmatic children and adolescents aged 10 to 19 compared to their baseline values. It is designed to track over a period of six consecutive months lung function parameters, lung inflammation, asthma symptoms and burden, medication adherence, and passively recorded nocturnal asthma symptoms and markers related to sleep quality.A teljes eredeti leírásKevesebb

This study is to evaluate the efficacy of the digital health assistant (DHA) "Alex" in improving asthma control in asthmatic children and adolescents aged 10 to 19 compared to their baseline values. It is designed to track over a period of six consecutive months lung function parameters, lung inflammation, asthma symptoms and burden, medication adherence, and passively recorded nocturnal asthma symptoms and markers related to sleep quality.

In Phase I (months 1-3), Digital Health Assistant (DHA) 's core functionality will be deployed.

In Phase II (months 3-6), the platform will be augmented with lung-function-fluctuations analysis-informed therapeutic recommendations, allowing to quantify the incremental benefit of targeted decision support beyond the gamified DHA alone.

An embedded qualitative study will be conducted to evaluate acceptability of and engagement with the DHA.

Bevonási feltételek: Written informed assent or consent, and parental/caregivers consent, depending on age; Age 10 to 19 years; Sufficient understanding of the Romanian language; Digital literacy, including the parents/caregivers, as assessed by the treating physician and/or by the recruiting healthcare provider using a multiple-choice questionnaire administered to the patient and their parents after a brief introduction to the functionalities of the Alex app; Confirmed asthma, i.e., history of recurrent wheeze, at least one spirometry in the three years prior to inclusion showing reversible obstruction (increase in forced expiratory volume at one second (FEV1) of ≥12% and/or ≥200ml) and/or a positive airway challenge test142; Participants need to be under treatment with regular prescribed asthma drugs, including inhaled corticosteroids, Long-acting β adrenoceptor agonists (LABA), and/or leukotriene receptor antagonists at recruitment, with no change in their medication in the last month; Enrolled in the observational study; Have had access to the DHA for at least 6 weeks; Provide informed assent (and parental/guardian consent where applicable) or consent, according to age; Able to participate in interviews or group discussions in Romanian.

Kizáró feltételek: Acute asthma exacerbation requiring systemic corticosteroids within four weeks prior to recruitment; Substance abuse as per urinary drug test; Qualitative study population:; Withdrawn from the observational study prior to data collection for qualitative work; Underlying chronic respiratory disease other than asthma (cystic fibrosis, primary ciliary dyskinesia); Acute lower respiratory tract infections (e.g., pneumonia, bronchitis) diagnosed by physician within past 4 to 6 weeks. For tuberculosis, see next exclusion criterion; Active tuberculosis as per Quantiferon test; Inability to perform adequate lung function measurements due to physical and/or intellectual disability; Not willing to use smartphones; Other causes of nocturnal cough such as postnasal drip, and vocal cord dysfunction; Active smoking as per urinary Cotinin test; Significant cognitive or communication difficulties that would limit participation in interviews or group discussions.

Observational study population:.

ClinicalTrials.gov NCT07472283